Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients

Abstract

A predominant isolated severe enthesitis pattern of SpA may develop under VDZ therapy with severe disease in 8% of cases. Most cases continued VDZ therapy.